Toward a CRISPR-based mouse model of -deficient clear cell kidney cancer: Initial experience and lessons learned.

Proceedings of the National Academy of Sciences of the United States of America
Authors
Keywords
Abstract

CRISPR is revolutionizing the ability to do somatic gene editing in mice for the purpose of creating new cancer models. Inactivation of the tumor suppressor gene is the signature initiating event in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). Such tumors are usually driven by the excessive HIF2 activity that arises when the gene product, pVHL, is defective. Given the pressing need for a robust immunocompetent mouse model of human ccRCC, we directly injected adenovirus-associated viruses (AAVs) encoding sgRNAs against and other known/suspected ccRCC tumor suppressor genes into the kidneys of C57BL/6 mice under conditions where Cas9 was under the control of one of two different kidney-specific promoters ( or 8) to induce kidney tumors. An AAV targeting , and reproducibly caused macroscopic ccRCCs that partially resembled human ccRCC tumors with respect to transcriptome and cell of origin and responded to a ccRCC standard-of-care agent, axitinib. Unfortunately, these tumors, like those produced by earlier genetically engineered mouse ccRCCs, are HIF2 independent.

Year of Publication
2024
Journal
Proceedings of the National Academy of Sciences of the United States of America
Volume
121
Issue
41
Pages
e2408549121
Date Published
10/2024
ISSN
1091-6490
DOI
10.1073/pnas.2408549121
PubMed ID
39365820
Links